Zurich Cantonal Bank
KALV

Zurich Cantonal Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Zurich Cantonal Bank’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,868
Closed -$289K – 3043
2025
Q4 		$289K Buy
+17,868
New +$237K ﹤0.01% 2077

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zurich Cantonal Bank's KALV Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 24,296 shares worth $489K. The stake represents ﹤0.01% of the portfolio and ranks #1842 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in KALV as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in KALV in Q1 2021 and has held it in 10 quarters since. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Zurich Cantonal Bank held 24,296 shares of KalVista Pharmaceuticals worth $489K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1842 holding.
  • Zurich Cantonal Bank first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.